• Applied Biological Chemistry
• /
• 제40권1호
• /
• pp.23-29
• /
• 1997

7-Aminocephalosporanic acid (7-ACA)로부터 새로운 구조의 ${\beta}-lactam$계 항생물질을 개발하기 위한 목적으로 7- ACA의 $C_3$ 위치에 thio1기를 도입하고 $C_7$위치 aminothiazole기를 결합시킨 신규 화합물 (YH-487)을 제조한 다음 이의 구조 확인과 항균활성, 작용기전, ${\beta}-lactamase$에 대한 안정성, 다른 항생물질과의 병용 효과 등을 검토한 결과 YH-487은 세균에 대한 항균활성과 살균력이 CTX보다 우수한 신규의 제3세대 cephem계 물질이었다. 또한 YH-487의 살균작용 메카니즘은 PBP-lA, PBP-1B와 PBP-3의 친화성에 의한 세균의 세포벽 합성저해에 의한 것이었다. ${\beta}-lactamase$에 대한 안정성은 E. coli가 생성하는 TEM-1 type Pcase에는 cefotiam 또는 cefotaxime과 동등한 수준이었으나 Stahylococcus aureus가 생성하는 Pcase와 Pseudomonas aeruginosa가 생성하는 CSase와 Proteus vulgaris 생성의 Cxase에는 cefotiam 또는 cefotaxime 보다 높은 안정성을 나타내어 ${\beta}-lactamase$에 대해 매우 안정한 약물임을 나타내었다. 한편 다른 항생물질과의 병용효과 실험결과는 gentamicin, tobramycin 그리고 amikacin과 병용시 녹농균에 대하여 상승효과가 인정되었고 Enterobacter cloacae에 대하여는 amikacin과 병용시 상승작용이 있었다.

• 한국독성학회:학술대회논문집
• /
• 한국독성학회 2001년도 International Symposium on Dietary and Medicinal Antimutgens and Anticarcinogens
• /
• pp.180-180
• /
• 2001

The mutagenic potency of a new antibiotics, IDC- 7181, was evaluated using the mutagenicity tests including Ames, chromosome aberration and micronucleus tests. In bacterial reversion assay, IDC-7181 did not show any mutagenic response in the absence or presence of S9 mixture with Salmonella typhimurium TA98, TAlOO, TA1535 and TA1537 and E. coli WP2uvrA-(100, 50, 25, 12.5 and 6.25 $\mu\textrm{g}$/plate).(omitted)

• 공업화학
• /
• 제23권5호
• /
• pp.429-432
• /
• 2012

최근 항생제에 대한 내성이 빠르게 확산됨에 따라 이를 극복하기 위해 새로운 항생제들을 찾기 위한 노력이 많은 연구자들에 의해 이루어지고 있다. 미생물의 외부공격에 대해 모든 생명체들은 방어물질을 분비하거나 내재하고 있는 데 그 중 하나가 항균 펩타이드이며, 전 세계적으로 활발한 연구가 이루어지고 있고 새로운 차세대 항생제로써 인식 되어진다. 이에 본 총설에서는 항균 펩타이드의 미생물에 대한 항생활성, 작용기작과 개발현황에 대해 고찰하고자 한다.

• 한국산학기술학회:학술대회논문집
• /
• 한국산학기술학회 2001년도 춘계학술대회 발표논문집
• /
• pp.295-297
• /
• 2001

본 발명의 Puromycin 유도체인 Cystocin 화합물은 유기 합성에 의해 제조된 물질이 아니라 방선균 계열의 신균주인 Streptamyces sp GCA0001로부터 추출된 신규 물질로서, 항박테리아, 항종양 및 항바이러스 활성 등의 생물학적 미생물 활성면에서 종래의 Puromycin 화합물에 비해 현저히 뛰어난 효과를 지니고 있고 Streptomyces sp GCA0001로부터 추출, 분리 및 정제 과정을 통해 제조된 자연의 선택의 과정을 거친 화합물이므로, Puromycin을 대체할 수 있는 획기적인 물질로 볼 수 있다.

• Journal of Microbiology and Biotechnology
• /
• 제15권1호
• /
• pp.86-90
• /
• 2005

Strain M-18 was isolated from the rhizosphere soil of sweet melon, using 1-aminocyclopropane-1-carboxylate (ACC) as a sole nitrogen source. Its phenotypic characteristics, metabolic tests, and 16S rDNA sequence were analyzed. The antibiotics secreted by strain M-18 were determined to be phenazine 1-carboxylic acid and pyoluteorin. These data showed that strain M-18 was a new fluorescent Pseudomonas strain that produced both phenazine 1-carboxylic acid and pyoluteorin, some features being similar to Pseudomonas aeruginosa and Pseudomonas fluorescens. Therefore, the strain M-18 appears to be the first pseudomonad described to date that is capable of producing both phenazine 1-carboxylic acid and pyoluteorin.

• 대한화학회지
• /
• 제38권7호
• /
• pp.521-525
• /
• 1994

새로운 cephalosporin 항생물질인 7-[(3,4-dihydro-6-methoxycarbonyl-2,2-dimethyl-2H-1,4-thiazin-3-yl)acetamido]-3-heterocyclothiomethyl-3-cephem-4-carboxylic acid 유도체(2a∼2d)들을 합성하여, 구조변화에 대한 항균활성을 측정하였다. 그 중에서 7-[(3,4-dihydro-6-methoxycarbonyl-2,2-dimethyl-2H-1,4-thiazin-3-yl)acetamido]-3-[(2-methyl-1,3,4-thiadiazol-5-yl)thiomethyl]-3-cephem-4-carboxylic acid가 그람양성 및 음성균에 대하여 광범위한 향균능력ㅇ르 나타내었다.

• 대한소화기학회지
• /
• 제72권5호
• /
• pp.237-244
• /
• 2018

While the prevalence of Helicobacter pylori (H. pylori) infection is decreasing in Korea, the incidence of gastric cancer remains high, emphasizing the importance of H. pylori eradication. A new treatment strategy is needed as the eradication rate with standard triple therapy, which is currently the standard first-line regimen for H. pylori infection, has decreased below the optimum level. The major cause of eradication failure is increased antibiotic resistance. Sequential, concurrent, and hybrid therapies that include clarithromycin produce higher eradication rates than conventional standard triple therapy. However, the effectiveness of these treatments is limited in regions where the resistance rate to various antibiotics is high. Bismuth quadruple therapy is another alternative therapy, but again the eradication rate is not sufficiently high. Tailored therapy based on individual characteristics, including antibiotic susceptibility, may be ideal, but there are several limitations for clinical application and further research is needed. New potassium-competitive acid blocker-based therapies could emerge as effective alternatives in the near future. A consensus is needed to establish a strategy for applying new eradication therapies in Korea.

• Applied Biological Chemistry
• /
• 제36권6호
• /
• pp.476-480
• /
• 1993

제초성항생물질인 maculosin과 phenylacetic acid를 생산하는 균주를 Streptomyces rochei로 동정하였다. 동정은 형태학적 및 생리학적 특성시험에 기초하였다. 이 균주는 진균류인 Alternaria altenata 외에 maculosin의 생성이 보고된 최초의 Streptomyces 속 균주이다.

• 한국자기공명학회논문지
• /
• 제6권1호
• /
• pp.69-77
• /
• 2002

During the screening of material which has the antimicrobial activity against aminoglycoside-resistant bacteria, A new material $\varepsilon$-(L-$\beta$-Iysine) polypeptide from a culture medium of Streptomyces sp.(DWGS2) was isolated, and the structure and the physicochemical properties of the new material were elucidated. The new material was separated by column chromatography of the culture medium using Dowex1$\times$2, Silica gel, and Sephadex LH20 etc. The chemical structure and molecular weight were determined with the data of various NMR experiments, MALDI mass, and ESI mass experiments. The antimicrobial activity of $\varepsilon$-(L-$\beta$-Iysine) polypeptide is not only better than equal to the activity of known aminoglycoside type of antibiotics(MIC=3.125 - 6.25ug/mL) but also effective against aminoglycoside-resistant bacteria and fungi. If the mechanism of antimicrobial activity against aminoglycoside- resistant bacteria is figured out, the $\varepsilon$-(L-$\beta$-Iysine) polypeptide can be utilized for the treatment of diseases caused by aminoglycoside-resistant bacteria.

• Mycobiology
• /
• 제43권1호
• /
• pp.9-13
• /
• 2015

Medicinal fungi, taken whole or as various forms of extracts, have been used to alleviate, cure or prevent human ailments since pre-historic times. In particular, Asian cultures have incorporated a variety of mushrooms into their medical practices. Chemically pure, bioactive metabolites from fungi have been a mainstay of modern pharmacological research and in addition to antibiotics, include anticancer agents, immunosuppressants, enzyme inhibitors, antagonist and agonists of hormones, and a variety of psychotropic substances. However, to date not many studies have focused on the possible health benefits of odorant volatile organic compounds (i.e., gas phase compounds). An analysis of these compounds for their health related effects will expand the range of compounds available for the treatment of chronic and acute diseases. This review highlights phenolic acids and monoterpenes from Asian medicinal mushrooms (AMMs), which not only produce pleasant odors but also have antioxidant and antibacterial effects. Odorant bioactive volatile phase compounds from medicinal mushrooms remain an essentially untapped source for future medicines, and AMMs remain a promising resource for future pharmacological research.